

Figure S1. Inhibition of TP2-5- and TP2-6-induced epidermal growth factor receptor (EGFR) activation by small-molecule tyrosine kinase inhibitors. Serum-starved HaCaT cells were pretreated with tyrosine kinase inhibitors, Gefitinib (10 μM) or PD158780 (10 μM), for 2 h and then incubated with 3.91 μg/ml of TP2-5 (A) or TP2-6 (B) for 24 h. Phosphorylated EGFR (p-EGFR) levels were detected by immunoblotting. α-Tubulin and GAPDH were used as loading controls.